Infinity Pharmaceuticals, Inc. (INFI) insider have most recently took part in a trading activity. On Dec 6, 2017 Bloch Lawrence E, President bought 500,000 shares having total worth of $905,000 at the price of $1.81 per share, following the transaction a total of 589,903 shares owned by Bloch Lawrence E.
Furthermore, over the past 12 months , the stock was traded 5 times by insiders. In 2 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.
Shares of Infinity Pharmaceuticals, Inc. (INFI) traded down 5% on Dec 6, 2017, hitting $1.71. 5,042,787 shares of the company’s stock traded hands. Infinity Pharmaceuticals, Inc. has a 52 week low of $0.93 and a 52 week high of $3.73. The company’s market cap is $77 million.
Infinity Pharmaceuticals, Inc. (INFI) last announced its earnings results on Nov 7, 2017. The company reported -0.14 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.21 by $0.07. The company had revenue of $6 million for the quarter, compared to the consensus estimate of $15 million. During the same quarter in the previous year, the company posted -0.39 earnings per share.
|earnings per share||-0.14||-0.34||-0.21||-0.46||-0.39||-1.20||-0.82||-0.80||0.84||-0.78|
Infinity Pharmaceuticals, Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998, the Company changed its name to Discovery Partners International, Inc., or DPI. On September 12, 2006, DPI completed a merger with Infinity Pharmaceuticals, Inc., or IPI, to which a wholly-owned subsidiary of DPI merged with and into IPI. IPI was the surviving corporation in the merger, changed its name to Infinity Discovery, Inc., or IDI, and became a wholly owned subsidiary of DPI. The Company changed its corporate name from Discovery Partners International, Inc. to Infinity Pharmaceuticals, Inc. The Company discovers, develops, and delivers medicines for the treatment of cancer and related conditions. The Company’s product candidate is saridegib, a novel, potent, oral molecule that inhibits the Hedgehog pathway by binding to the Smoothened receptor, a protein that plays a critical role in the malignant activation of the Hedgehog pathway. The Company is evaluating saridegib in a randomized, double-blind Phase 2 clinical trial to assess the safety and efficacy of saridegib compared to placebo in approximately 140 patients with metastatic or locally advanced, inoperable chondrosarcoma. The Company is also enrolling patients in an exploratory Phase 2 clinical trial evaluating the safety and efficacy of saridegib in patients with myelofibrosis. Retaspimycin hydrochloride (HCl), , is a novel, potent and selective inhibitor of heat shock protein 90, or Hsp90. Cancer cells depend on Hsp90 to maintain many proteins critical for cancer growth, proliferation and survival in a functional state. Retaspimycin HCl is currently being evaluated in a randomized, double-blind Phase 2 clinical trial in combination with docetaxel, a chemotherapy, compared to placebo and docetaxel in approximately 200 patients with second- or third-line non-small cell lung cancer, or NSCLC, who are naive to docetaxel treatment and have a history of heavy smoking. The Company is also enrolling patients in a Phase 1b/2 trial to explore the safety and efficacy of retaspimycin HCl in combination with everolimus, an mTOR inhibitor, in NSCLC patients with a KRAS mutation. The Company’s compound in this PI3K Inhibitor Program is IPI-145, a potent, orally-available inhibitor of PI3K-delta and PI3K-gamma. PI3Ks, are a family of enzymes involved in key immune cell functions, including cell proliferation and survival, cell differentiation, and cellular trafficking. PI3K-delta and PI3K-gamma, two isoforms of PI3K, play key roles in inflammatory and autoimmune diseases. Government authorities in the United States and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, storage, recordkeeping, approval, promotion, labeling, advertising, distribution, marketing, post-approval monitoring and reporting, sampling, and export and import of pharmaceutical products such as those it is developing.
Latest posts by William White (see all)
- Recent Insider Trading: Hecla Mining Company $HL - December 15, 2017
- Insider Trading Watch List: Dakota Territory Resource Corp. $DTRC - December 15, 2017
- Notable Insider Trading: Western Asset Managed Municipals Fund, Inc. $MMU - December 15, 2017